Biomarkers of liver cell death

Journal of Hepatology

Volumn 60, Issue 5, 2014, Pages 1063-1074

  Eguchi, Akiko ^a   Wree, Alexander ^a   Feldstein, Ariel E ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Acute liver injury; Biomarker; Cell death; Chronic liver injury

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 18; FAS ANTIGEN; FAS LIGAND; HIGH MOBILITY GROUP B1 PROTEIN; MICRORNA; PEPTIDE FRAGMENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANIMAL; BIOLOGICAL MODEL; BLOOD; CELL DEATH; GENETICS; HUMAN; LIVER CELL; LIVER DISEASE; MEMBRANE MICROPARTICLE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD95; BIOLOGICAL MARKERS; CELL DEATH; CELL-DERIVED MICROPARTICLES; FAS LIGAND PROTEIN; HEPATOCYTES; HMGB1 PROTEIN; HUMANS; KERATIN-18; LIVER DISEASES; MICRORNAS; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84898820010     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.12.026     Document Type: Review

References (137)

1. H. Malhi, M.E. Guicciardi, and G.J. Gores Hepatocyte death: a clear and present danger Physiol Rev 90 2010 1165 1194
2. J. Park et al. Hepatitis C virus infection enhances TNFalpha-induced cell death via suppression of NF-kappaB Hepatology 56 2012 831 840
3. A. Dolganiuc et al. Autophagy in alcohol-induced liver diseases Alcohol Clin Exp Res 36 2012 1301 1308
4. H. Bantel, and K. Schulze-Osthoff Mechanisms of cell death in acute liver failure Front Physiol 3 2012 79
5. H. Jaeschke, M.R. McGill, and A. Ramachandran Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity Drug Metab Rev 44 2012 88 106
6. A. Canbay, S. Friedman, and G.J. Gores Apoptosis: the nexus of liver injury and fibrosis Hepatology 39 2004 273 278
7. A. Canbay et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic Lab Invest 83 2003 655 663
8. H.C. Masuoka, M.E. Guicciardi, and G.J. Gores Caspase inhibitors for the treatment of hepatitis C Clin Liver Dis 13 2009 467 475
9. S.L. Friedman et al. Therapy for fibrotic diseases: nearing the starting line Sci Transl Med 5 2013 167sr1
10. H.M. Ni et al. Targeting autophagy for the treatment of liver diseases Pharmacol Res 66 2012 463 474
11. S.L. Fink, and B.T. Cookson Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells Infect Immun 73 2005 1907 1916
12. G. Kroemer et al. Classification of cell death: recommendations of the nomenclature committee on cell death 2009 Cell Death Differ 16 2009 3 11
13. M. Komatsu Liver autophagy: physiology and pathology J Biochem 152 2012 5 15
14. A. Wree et al. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation and fibrosis Hepatology 2013 10.1002/hep.26592
15. S. Roychowdhury et al. Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury Hepatology 57 2013 1773 1783
16. S.J. Riedl, and Y. Shi Molecular mechanisms of caspase regulation during apoptosis Nat Rev Mol Cell Biol 5 2004 897 907
17. M. Amir, and M.J. Czaja Autophagy in non-alcoholic steatohepatitis Expert Rev Gastroenterol Hepatol 5 2011 159 166
18. D. Gozuacik, and A. Kimchi Autophagy and cell death Curr Top Dev Biol 78 2007 217 245
19. H.M. Shen, and P. Codogno Autophagic cell death: loch ness monster or endangered species? Autophagy 7 2011 457 465
20. M.C. Maiuri et al. Self-eating and self-killing: crosstalk between autophagy and apoptosis Nat Rev Mol Cell Biol 8 2007 741 752
21. T. Hara et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice Nature 441 2006 885 889
22. Y. Wang et al. Macroautophagy and chaperone-mediated autophagy are required for hepatocyte resistance to oxidant stress Hepatology 52 2010 266 277
23. N. Holler et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule Nat Immunol 1 2000 489 495
24. L. Galluzzi, O. Kepp, and G. Kroemer RIP kinases initiate programmed necrosis J Mol Cell Biol 1 2009 8 10
25. B.T. Cookson, and M.A. Brennan Pro-inflammatory programmed cell death Trends Microbiol 9 2001 113 114
26. S.L. Fink, and B.T. Cookson Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages Cell Microbiol 8 2006 1812 1825
27. A. Rasola, and P. Bernardi The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis Apoptosis 12 2007 815 833
28. R.S. Hotchkiss et al. Cell death N Engl J Med 361 2009 1570 1583
29. G.J. Gores, B. Herman, and J.J. Lemasters Plasma membrane bleb formation and rupture: a common feature of hepatocellular injury Hepatology 11 1990 690 698
30. B. Schutte et al. Keratin 8/18 breakdown and reorganization during apoptosis Exp Cell Res 297 2004 11 26
31. C. Caulin, G.S. Salvesen, and R.G. Oshima Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis J Cell Biol 138 1997 1379 1394
32. N.O. Ku, J. Liao, and M.B. Omary Apoptosis generates stable fragments of human type I keratins J Biol Chem 272 1997 33197 33203
33. M.C. Abraham, and S. Shaham Death without caspases, caspases without death Trends Cell Biol 14 2004 184 193
34. G. Kramer et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18 Cancer Res 64 2004 1751 1756
35. A. Wieckowska, A.J. McCullough, and A.E. Feldstein Noninvasive diagnosis and monitoring of non-alcoholic steatohepatitis: present and future Hepatology 46 2007 582 589
36. G. Musso et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity Ann Med 43 2011 617 649
37. R. Vuppalanchi et al. Changes in serum cytokeratin 18 levels significantly predict changes in liver histology in adults with non-alcoholic steatohepatitis: results from the pivens trial Gastroenterology 144 2013 S951
38. N. Chalasani et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology Gastroenterology 142 2012 1592 1609
39. H. Bantel et al. Detection of apoptotic caspase activation in sera from patients with chronic HCV infection is associated with fibrotic liver injury Hepatology 40 2004 1078 1087
40. N. Seidel et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum Hepatology 42 2005 113 120
41. A.B. Jazwinski et al. Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis J Viral Hepat 19 2012 278 282
42. Y. Yilmaz et al. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with non-alcoholic steatohepatitis and chronic hepatitis C Med Sci Monit 15 2009 CR189 CR193
43. G.V. Papatheodoridis et al. Serum apoptotic caspase activity as a marker of severity in HBeAg-negative chronic hepatitis B virus infection Gut 57 2008 500 506
44. P. Van Eyken, and V.J. Desmet Cytokeratins and the liver Liver 13 1993 113 122
45. A. Gonzalez-Quintela et al. Serum cytokeratins in alcoholic liver disease: contrasting levels of cytokeratin-18 and cytokeratin-19 Alcohol 38 2006 45 49
46. P. Barros et al. Increased urinary levels of tissue polypeptide specific antigen (TPS) in alcoholics Anticancer Res 26 2006 1531 1534
47. V.J. Lavallard et al. Serum markers of hepatocyte death and apoptosis are non invasive biomarkers of severe fibrosis in patients with alcoholic liver disease PLoS One 6 2011 e17599
48. A. Rutherford, and R.T. Chung Acute liver failure: mechanisms of hepatocyte injury and regeneration Semin Liver Dis 28 2008 167 174
49. L.P. Bechmann et al. Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury J Hepatol 53 2010 639 647
50. A. Rutherford et al. Development of an accurate index for predicting outcomes of patients with acute liver failure Gastroenterology 143 2012 1237 1243
51. S. Nagata, and P. Golstein The Fas death factor Science 267 1995 1449 1456
52. M.E. Peter, and P.H. Krammer The CD95(APO-1/Fas) DISC and beyond Cell Death Differ 10 2003 26 35
53. N. Alkhouri, C. Carter-Kent, and A.E. Feldstein Apoptosis in non-alcoholic fatty liver disease: diagnostic and therapeutic implications Expert Rev Gastroenterol Hepatol 5 2011 201 212
54. P.R. Galle et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage J Exp Med 182 1995 1223 1230
55. S. Strand et al. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis Nat Med 4 1998 588 593
56. J. Taieb et al. Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease Lancet 351 1998 1930 1931
57. A.E. Feldstein et al. Hepatocyte apoptosis and fas expression are prominent features of human non-alcoholic steatohepatitis Gastroenterology 125 2003 437 443
58. C. Zou et al. Lack of Fas antagonism by Met in human fatty liver disease Nat Med 13 2007 1078 1085
59. M. Tanaka et al. Fas ligand in human serum Nat Med 2 1996 317 322
60. M.C. Turi et al. Serum sFas/sFasL ratio in systemic lupus erythematosus (SLE) is a function of age Arch Gerontol Geriatr 49 2009 221 226
61. K. Suzuki et al. Serum levels of soluble Fas ligand in patients with acute and fulminant hepatitis: relationship with soluble Fas, tumor necrosis factor-alpha and TNF receptor-1 Hepatol Res 17 2000 19 30
62. H. Nakae, K. Narita, and S. Endo Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure J Crit Care 16 2001 59 63
63. T.I. Tamimi et al. An apoptosis panel for non-alcoholic steatohepatitis diagnosis J Hepatol 54 2011 1224 1229
64. C. Liedtke, and C. Trautwein The role of TNF and Fas dependent signaling in animal models of inflammatory liver injury and liver cancer Eur J Cell Biol 91 2012 582 589
65. H. Tilg The role of cytokines in non-alcoholic fatty liver disease Dig Dis 28 2010 179 185
66. A. Wree et al. Obesity affects the liver - the link between adipocytes and hepatocytes Digestion 83 2011 124 133
67. G.S. Hotamisligil, N.S. Shargill, and B.M. Spiegelman Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance Science 259 1993 87 91
68. J. Crespo et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in non-alcoholic steatohepatitis patients Hepatology 34 2001 1158 1163
69. P.S. Ribeiro et al. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of non-alcoholic and alcoholic steatohepatitis patients Am J Gastroenterol 99 2004 1708 1717
70. R.A. Black et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells Nature 385 1997 729 733
71. A.P. Huovila et al. Shedding light on ADAM metalloproteinases Trends Biochem Sci 30 2005 413 422
72. C.J. McClain, and D.A. Cohen Increased tumor necrosis factor production by monocytes in alcoholic hepatitis Hepatology 9 1989 349 351
73. C.J. McClain et al. Cytokines in alcoholic liver disease Semin Liver Dis 19 1999 205 219
74. M.E. Felver et al. Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis Alcohol Clin Exp Res 14 1990 255 259
75. G.L. Bird et al. Increased plasma tumor necrosis factor in severe alcoholic hepatitis Ann Intern Med 112 1990 917 920
76. M. Manco et al. Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric non-alcoholic fatty liver disease Am J Clin Pathol 127 2007 954 960
77. J.M. Hui et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 40 2004 46 54
78. Y.S. Huang et al. Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study Zhonghua Yi Xue Za Zhi (Taipei) 62 1999 327 333
79. S. Kakumu et al. Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease Clin Exp Immunol 109 1997 458 463
80. P. Schneider et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB Immunity 7 1997 831 836
81. M. MacFarlane TRAIL-induced signalling and apoptosis Toxicol Lett 139 2003 89 97
82. N.S. Azahri, and M.M. Kavurma Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand Cell Mol Life Sci 70 2013 3617 3629
83. C. Falschlehner et al. TRAIL and other TRAIL receptor agonists as novel cancer therapeutics Adv Exp Med Biol 647 2009 195 206
84. Y. Saitou et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases Hum Pathol 36 2005 1066 1073
85. B. Mundt et al. Involvement of TRAIL and its receptors in viral hepatitis FASEB J 17 2003 94 96
86. H. Malhi et al. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity Gut 56 2007 1124 1131
87. A. Kahraman et al. Major histocompatibility complex class I-related chains A and B (MIC A/B): a novel role in non-alcoholic steatohepatitis Hepatology 51 2010 92 102
88. X. Yan et al. STRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease Immunogenetics 61 2009 551 556
89. L.H. Han et al. Detection of soluble TRAIL in HBV infected patients and its clinical implications World J Gastroenterol 8 2002 1077 1080
90. T. Vaccari et al. Hmg4, a new member of the Hmg1/2 gene family Genomics 49 1998 247 252
91. Q.W. Yang et al. High-mobility group protein box-1 and its relevance to cerebral ischemia J Cereb Blood Flow Metab 30 2010 243 254
92. Z.S. Guo et al. Life after death: targeting high mobility group box 1 in emergent cancer therapies Am J Cancer Res 3 2013 1 20
93. I.E. Dumitriu et al. HMGB1: guiding immunity from within Trends Immunol 26 2005 381 387
94. P. Scaffidi, T. Misteli, and M.E. Bianchi Release of chromatin protein HMGB1 by necrotic cells triggers inflammation Nature 418 2002 191 195
95. C.W. Bell et al. The extracellular release of HMGB1 during apoptotic cell death Am J Physiol Cell Physiol 291 2006 C1318 C1325
96. H. Kazama et al. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein Immunity 29 2008 21 32
97. T. Bonaldi et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion EMBO J 22 2003 5551 5560
98. J.H. Youn, and J.S. Shin Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion J Immunol 177 2006 7889 7897
99. D.J. Antoine et al. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo Toxicol Sci 112 2009 521 531
100. J. Evankovich et al. High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity J Biol Chem 285 2010 39888 39897
101. M. Lamkanfi et al. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia J Immunol 185 2010 4385 4392
102. B. Lu et al. Novel role of PKR in inflammasome activation and HMGB1 release Nature 488 2012 670 674
103. N. Kamo et al. ASC/caspase-1/IL-1beta signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia/reperfusion injury Hepatology 58 2013 351 362
104. Q. Yang et al. The role of intracellular high-mobility group box 1 in the early activation of Kupffer cells and the development of Con A-induced acute liver failure Immunobiology 218 2013 1284 1292
105. D.J. Antoine et al. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity J Hepatol 56 2012 1070 1079
106. D.J. Antoine et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital Hepatology 58 2013 777 787
107. L. He, and G.J. Hannon MicroRNAs: small RNAs with a big role in gene regulation Nat Rev Genet 5 2004 522 531
108. J. Lu et al. MicroRNA expression profiles classify human cancers Nature 435 2005 834 838
109. G.A. Calin, and C.M. Croce MicroRNA signatures in human cancers Nat Rev Cancer 6 2006 857 866
110. A. Esquela-Kerscher, and F.J. Slack Oncomirs - microRNAs with a role in cancer Nat Rev Cancer 6 2006 259 269
111. G. Szabo, and S. Bala MicroRNAs in liver disease Nat Rev Gastroenterol Hepatol 10 2013 542 552
112. J. Trebicka et al. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis J Hepatol 58 2013 234 239
113. K. Wang et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury Proc Natl Acad Sci U S A 106 2009 4402 4407
114. Y.W. Su et al. A panel of serum microRNAs as specific biomarkers for diagnosis of compound- and herb-induced liver injury in rats PLoS One 7 2012 e37395
115. P.J. Starkey Lewis et al. Circulating microRNAs as potential markers of human drug-induced liver injury Hepatology 54 2011 1767 1776
116. P.J. Starkey Lewis et al. Serum microRNA biomarkers for drug-induced liver injury Clin Pharmacol Ther 92 2012 291 293
117. H. Yamada et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122, and miR-451) and non-alcoholic fatty liver Clin Chim Acta 424C 2013 99 103
118. M. Trajkovski et al. MicroRNAs 103 and 107 regulate insulin sensitivity Nature 474 2011 649 653
119. J. Joven et al. Plant-derived polyphenols regulate expression of miRNA paralogs miR-103/107 and miR-122 and prevent diet-induced fatty liver disease in hyperlipidemic mice Biochim Biophys Acta 1820 2012 894 899
120. S. Bala et al. Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection J Transl Med 10 2012 151
121. S. Bala et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases Hepatology 56 2012 1946 1957
122. A.M. Lakner et al. Inhibitory effects of microRNA 19b in hepatic stellate cell-mediated fibrogenesis Hepatology 56 2012 300 310
123. C. Roderburg et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis Hepatology 53 2011 209 218
124. S.K. Venugopal et al. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation Am J Physiol Gastrointest Liver Physiol 298 2010 G101 G106
125. M. Iizuka et al. Induction of microRNA-214-5p in human and rodent liver fibrosis Fibrogenesis Tissue Repair 5 2012 12
126. T. Ogawa et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis Gut 61 2012 1600 1609
127. S.F. Mause, and C. Weber Microparticles: protagonists of a novel communication network for intercellular information exchange Circ Res 107 2010 1047 1057
128. P. Diehl et al. Microparticles: major transport vehicles for distinct microRNAs in circulation Cardiovasc Res 93 2012 633 644
129. A. Yuan et al. Transfer of microRNAs by embryonic stem cell microvesicles PLoS One 4 2009 e4722
130. O. Morel et al. Microparticles: a critical component in the nexus between inflammation, immunity, and thrombosis Semin Immunopathol 33 2011 469 486
131. P.E. Rautou et al. Microparticles, vascular function, and atherothrombosis Circ Res 109 2011 593 606
132. R.P. Witek et al. Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in hepatic endothelial cells Gastroenterology 136 2009 320 330 [e2]
133. D. Povero et al. Lipid-induced toxicity stimulates hepatocytes to release angiogenic microparticles that require vanin-1 for uptake by endothelial cells Sci Signal 6 2013 ra88
134. M. Schmelzle et al. Increased plasma levels of microparticles expressing CD39 and CD133 in acute liver injury Transplantation 95 2013 63 69
135. P.E. Rautou et al. Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis Gastroenterology 143 2012 166 176 [e6]
136. M. Kornek et al. Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or non-alcoholic steatohepatitis Gastroenterology 143 2012 448 458
137. D. Schuppan, and M. Pinzani Anti-fibrotic therapy: lost in translation? J Hepatol 56 2012 S66 S74